Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Cumulative risk of skin tumours in patients with Lynch syndrome

Cumulative risk of skin tumours in patients with Lynch syndrome Research letter Table 1 Baseline characteristics of the 331 included patients and skin Cumulative risk of skin tumours in patients tumours with Lynch syndrome Male sex, n (%) 136 (411) DOI: 10.1111/bjd.16552 Deceased, n (%) 11 (33) Age at the end of follow-up, median (range) DEAR EDITOR, Lynch syndrome (LS) is an autosomal dominant Patients alive (n = 320) 50 (19–88) years At time of death (n = 11) 66 (42–82) years disorder characterized by a predisposition to colorectal cancer Mutation, n (%) of patients and extracolonic malignancies. LS is caused by a germline MLH1 74 (224) mutation in one of the four DNA mismatch repair genes MSH2/EPCAM 118 (356) (MLH1, MSH2, MSH6 and PMS2) or loss of expression of MSH2 MSH6 92 (278) due to deletion in the EPCAM gene. Muir–Torre syndrome PMS2 47 (142) (MTS) is considered to be a variant of LS, in which patients Medical history of keratoacanthoma, Bowen disease and/or present with sebaceous neoplasms and/or keratoacan- benign sebaceous lesions, n (%) 2,3 thomas. A few studies and case reports suggest a relation- Yes 18 (54) No 313 (946) ship between LS and other benign and (pre)malignant skin 4,5 Medical history of malignant skin tumour, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Dermatology Oxford University Press

Cumulative risk of skin tumours in patients with Lynch syndrome

Loading next page...
 
/lp/oxford-university-press/cumulative-risk-of-skin-tumours-in-patients-with-lynch-syndrome-LcUGK7sztw

References (8)

Publisher
Oxford University Press
Copyright
© 2018 British Association of Dermatologists
ISSN
0007-0963
eISSN
1365-2133
DOI
10.1111/bjd.16552
Publisher site
See Article on Publisher Site

Abstract

Research letter Table 1 Baseline characteristics of the 331 included patients and skin Cumulative risk of skin tumours in patients tumours with Lynch syndrome Male sex, n (%) 136 (411) DOI: 10.1111/bjd.16552 Deceased, n (%) 11 (33) Age at the end of follow-up, median (range) DEAR EDITOR, Lynch syndrome (LS) is an autosomal dominant Patients alive (n = 320) 50 (19–88) years At time of death (n = 11) 66 (42–82) years disorder characterized by a predisposition to colorectal cancer Mutation, n (%) of patients and extracolonic malignancies. LS is caused by a germline MLH1 74 (224) mutation in one of the four DNA mismatch repair genes MSH2/EPCAM 118 (356) (MLH1, MSH2, MSH6 and PMS2) or loss of expression of MSH2 MSH6 92 (278) due to deletion in the EPCAM gene. Muir–Torre syndrome PMS2 47 (142) (MTS) is considered to be a variant of LS, in which patients Medical history of keratoacanthoma, Bowen disease and/or present with sebaceous neoplasms and/or keratoacan- benign sebaceous lesions, n (%) 2,3 thomas. A few studies and case reports suggest a relation- Yes 18 (54) No 313 (946) ship between LS and other benign and (pre)malignant skin 4,5 Medical history of malignant skin tumour,

Journal

British Journal of DermatologyOxford University Press

Published: Aug 1, 2018

There are no references for this article.